- Home
- ERAS vs BWMX Comparison
ERAS vs BWMX Comparison
Compare ERAS & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- BWMX
- Stock Information
- Founded
- ERAS 2018
- BWMX 1995
- Country
- ERAS United States
- BWMX Mexico
- Employees
- ERAS N/A
- BWMX N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- BWMX Catalog/Specialty Distribution
- Sector
- ERAS Health Care
- BWMX Consumer Discretionary
- Exchange
- ERAS Nasdaq
- BWMX Nasdaq
- Market Cap
- ERAS 396.6M
- BWMX 360.5M
- IPO Year
- ERAS 2021
- BWMX N/A
- Fundamental
- Price
- ERAS $1.39
- BWMX $9.56
- Analyst Decision
- ERAS Strong Buy
- BWMX Strong Buy
- Analyst Count
- ERAS 6
- BWMX 1
- Target Price
- ERAS $4.83
- BWMX $22.50
- AVG Volume (30 Days)
- ERAS 1.4M
- BWMX 31.6K
- Earning Date
- ERAS 05-20-2025
- BWMX 04-24-2025
- Dividend Yield
- ERAS N/A
- BWMX 13.23%
- EPS Growth
- ERAS N/A
- BWMX N/A
- EPS
- ERAS N/A
- BWMX 0.74
- Revenue
- ERAS N/A
- BWMX $684,841,453.00
- Revenue This Year
- ERAS N/A
- BWMX $8.79
- Revenue Next Year
- ERAS N/A
- BWMX $6.14
- P/E Ratio
- ERAS N/A
- BWMX $12.60
- Revenue Growth
- ERAS N/A
- BWMX 4.87
- 52 Week Low
- ERAS $1.01
- BWMX $9.00
- 52 Week High
- ERAS $3.45
- BWMX $18.38
- Technical
- Relative Strength Index (RSI)
- ERAS 51.46
- BWMX 39.21
- Support Level
- ERAS $1.37
- BWMX $9.20
- Resistance Level
- ERAS $1.61
- BWMX $9.71
- Average True Range (ATR)
- ERAS 0.14
- BWMX 0.59
- MACD
- ERAS 0.00
- BWMX -0.02
- Stochastic Oscillator
- ERAS 45.68
- BWMX 28.00
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.